Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting Phase 2 Trials for DB00002 (Cetuximab)

Also known as: Head and Neck Squamous Cell Carcinoma

IndicationStatusPhase
DBCOND0043665 (Head and Neck Squamous Cell Carcinoma (HNSCC))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02270814Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaTreatment
NCT03082534Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaTreatment
NCT02268695Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCCTreatment